Safety syringe and methods for administration of a medicament dose by subject weight

ABSTRACT

An apparatus includes a syringe body and a plunger. The syringe body defines a volume configured to contain a medicament. A proximal end portion of the syringe body includes an engagement portion, and a distal end portion of the syringe body includes a delivery tip. A side wall of the syringe body includes a transparent window. The plunger has a distal end portion configured to move within the volume of the syringe body to convey the medicament. An engagement portion of the plunger is configured to interface with the engagement portion of the syringe body to limit rotation of the plunger about a longitudinal axis of the plunger. An outer surface of the plunger includes a series of indicia, at least one which is visible through the transparent window.

CROSS-REFERENCE TO RELATED APPLICATIONS

This application is a divisional of U.S. patent application Ser. No.14/966,097, entitled “Safety Syringe and Methods for Administration of aMedicament Dose by Subject Weight,” filed Dec. 11, 2015, which claimspriority to U.S. Provisional Application Ser. No. 62/092,234, entitled“Safety Syringe with Dosage by Weight,” filed Dec. 15, 2014, thedisclosure of each of which is incorporated herein by reference in itsentirety.

BACKGROUND

The embodiments described herein relate to syringes and methods foradministering a dose of medicament based on the subject's weight,height, age, or other characteristic.

Some known syringes for delivering dosages of a medicament include asyringe barrel with graduated markings and a plunger that is movablewithin the barrel to set the dosage and deliver the medicament. Thegraduated markings for such known syringes are often volumetric (i.e.,they indicate the volume of the medicament within the syringe), and thusa user must calculate, convert, or otherwise determine the correct dosebased on, among other things, the patient's weight, height and/or age.Additionally, the graduated markings are often very small, are sometimesprovided in confusing or unfamiliar units of measure (e.g., teaspoons ormilliliters), and require that the user align the plunger along the axisof motion to set the dosage. Moreover, certain medication regimensrequire that different amounts of the medicament be administered ondifferent days of the treatment. Accordingly, using such known syringesand methods can result in an unacceptable level of medication errorand/or “adverse drug events” because of improper dosing (delivering moreor less of a drug than the prescribed amount), noncompliance with theregimen (missing a day, administering the improper amount for a givenday), or the like.

Although such issues are prevalent with oral delivery ofover-the-counter drugs, such as ibuprofen, Tylenol®, cough syrup, or thelike, studies have shown that such issues also exist in hospital andclinical settings. For example, one study of adverse drug events athospitals estimated that although a large number of adverse drug eventsoccurred at the ordering stage, many occurred at the administeringstage. Bates, D. W., et al., “Incidence of Adverse Drug Events andPotential Adverse Drug Events,” Journal of the American MedicalAssociation, Jul. 5, 1995, Vol. 274, No. 1, pp. 29-30. Another studyevaluating the ability of 100 registered nurses to calculate the correctdosage for oral, intramuscular, and intravenous drugs showed an averageerror rate of about 20 percent or higher, depending on the type ofdelivery mechanism. Bindler, et al., “Medication Calculation Ability ofRegistered Nurses,” Journal of Nursing Scholarship, 1991, 23:221-224.

One proposed solution to reduce medication error and/or “adverse drugevents” is to deliver a predetermined dosage via a single-use prefilledsyringe or cartridge. Although convenient for some drugs and/ortherapeutic regimens, prefilled syringes are expensive, cumbersome tostore, and impractical for many drugs (e.g., over-the-counterpainkillers). Moreover, unless a caregiver maintains an inventory ofprefilled syringes tailored to a variety of different patients (e.g.,weight, age range, or the like), the use of prefilled syringes willstill require that the user calculate, convert or otherwise determinethe correct dose to be administered.

Other delivery devices for administering dosages, such as insulin pens,include dose-setting mechanisms that include rotatable caps or plungers,bulky multi-part container holders, and the like. Although these devicesmay be suitable for certain drugs and/or therapeutic regimens, such aschronic care situations (e.g., delivery of insulin), such known devicesare impractical for many other drugs and/or therapeutic regimens. Forexample, administering an over-the-counter cold medicine via anexpensive pen injector that requires adherence to specific instructionsfor use is impractical.

Thus, a need exists for improved methods and devices for easily andaccurately delivering medicaments via a syringe.

SUMMARY

Syringes for delivering a dose of medicament are described herein. Insome embodiments, an apparatus includes a syringe body and a plunger.The syringe body defines a volume configured to contain a medicament. Aproximal end portion of the syringe body includes an engagement portion,and a distal end portion of the syringe body includes a delivery tip. Aside wall of the syringe body includes a transparent window. The plungerhas a distal end portion configured to move within the volume of thesyringe body to convey the medicament. An engagement portion of theplunger is configured to interface with the engagement portion of thesyringe body to limit rotation of the plunger about a longitudinal axisof the plunger. An outer surface of the plunger includes a series ofindicia, at least one of which is visible through the transparentwindow.

BRIEF DESCRIPTION OF THE DRAWINGS

FIG. 1 is an exploded view schematic illustration of a syringe assemblyaccording to an embodiment.

FIGS. 2-4 are schematic illustrations of the syringe assembly shown inFIG. 1, in a first, second, and third configuration, respectively.

FIG. 5 is a front perspective view of a syringe assembly according to anembodiment.

FIGS. 6 and 7 are a front view and a side perspective view,respectively, of the syringe assembly shown in FIG. 5.

FIGS. 8 and 9 are a side view and a top view, respectively, of a portionof a syringe assembly according to an embodiment.

FIG. 10 is a front view of a syringe assembly according to anembodiment.

FIGS. 11 and 12 are front views of a syringe assembly according to anembodiment, in a first and second configuration, respectively.

FIG. 13 is a front view of the components of a syringe assemblyaccording to an embodiment.

FIG. 14 is a front perspective view of the components of a syringeassembly according to an embodiment.

FIG. 15 is a schematic illustration of a kit including a syringeassembly and a lock member according to an embodiment.

FIG. 16 is a schematic illustration of a portion of a kit including alock member according to an embodiment.

FIGS. 17A and 17B are bottom view schematic illustrations, each showinga delivery tip of a syringe assembly according to an embodiment.

FIG. 18 is a flow chart of a method of using a syringe assemblyaccording to an embodiment.

DETAILED DESCRIPTION

Syringes for easily and accurately delivering a dose of medicament aredescribed herein. In some embodiments, an apparatus includes a syringebody and a plunger. The syringe body defines a volume configured tocontain a medicament. A proximal end portion of the syringe bodyincludes an engagement portion, and a distal end portion of the syringebody includes a delivery tip. A side wall of the syringe body includes atransparent window. The plunger has a distal end portion configured tomove within the volume of the syringe body to convey the medicament. Anengagement portion of the plunger is configured to interface with theengagement portion of the syringe body to limit rotation of the plungerabout a longitudinal axis of the plunger. An outer surface of theplunger includes a series of indicia, at least one of which is visiblethrough the transparent window.

In some embodiments, an apparatus includes a syringe body and a plunger.The syringe body defines a volume configured to contain a medicament.The syringe body includes a proximal end flange including an engagementportion. A side wall of the syringe body includes a transparent window.The plunger has a distal end elastomeric member configured to movewithin the volume of the syringe body to convey the medicament. Anengagement portion of the plunger is configured to interface with theengagement portion of the syringe body to limit rotation of the plungerabout a longitudinal axis of the plunger. The flange defines an openingthrough which the elastomeric member can be removed. An outer surface ofthe plunger includes a series of indicia, at least one of which isvisible through the transparent window.

In some embodiments, a plunger can include a series of non-volumetricindicia. The non-volumetric indicia can be associated with a patient'sweight, height, age and/or any other suitable dose-settingcharacteristic. In some embodiments, the series of indicia can bearranged coaxially along a longitudinal axis of the plunger.

In some embodiments, an apparatus includes a syringe body, a set ofremovable labels and a plunger. The syringe body defines a volumeconfigured to contain a medicament. A side wall of the syringe bodyincludes a set of transparent windows, each of which corresponds to adifferent dose of a therapeutic regimen. In some embodiments, forexample, each window can correspond to a different day of the regimen. Aportion of the side wall surrounding each of the transparent windows isopaque. Each of the removable labels is configured to be coupled to theside wall of the syringe body to cover one of the transparent windows.The plunger has a distal end portion configured to move within thevolume of the syringe body to convey the medicament. An outer surface ofthe plunger includes a set of indicia, each of which corresponds to thedifferent dose of the therapeutic regimen. Each indicia is visiblethrough the corresponding transparent window when the correspondingremovable label from the set of removable labels is removed from theside wall of the syringe body.

In some embodiments, a kit includes a medicament container and a syringeassembly. The medicament container contains at least one dose of amedicament and defines an opening. The syringe assembly includes asyringe body and a plunger. A proximal end portion of the syringe bodyincludes an engagement portion. A distal end portion of the syringe bodyincludes a delivery tip configured to be disposed within the medicamentcontainer to withdraw the dose of the medicament from the container intoa volume defined by the syringe body. The syringe body includes atransparent window. A distal end portion of the plunger is configured tomove within the volume of the syringe body to convey the medicament. Anengagement portion of the plunger is configured to interface with theengagement portion of the syringe body to limit rotation of the plungerabout a longitudinal axis of the plunger. An outer surface of theplunger includes a set of dose indicia, at least one of which is visiblethrough the transparent window.

In some embodiments, the kit further includes a lock member removablycoupled to the proximal end portion of the syringe body and a proximalend portion of the plunger. The lock member is configured to limitmovement of the distal end portion of the plunger within the syringebody. The lock member includes an instruction indicia, such as, forexample, drug labeling, warnings, or the like.

In some embodiments, a method includes inserting a delivery tip of asyringe body, which defines a volume therein, into a medicamentcontainer. A plunger is moved in a proximal direction within the volumeof the syringe body to convey the medicament from the medicamentcontainer into the volume. The moving is performed until a dose indiciafrom a plurality of dose indicia on the plunger is visible through atransparent window defined by the syringe body. The plunger includes anengagement portion configured to interface with an engagement portion ofthe syringe body to limit rotation of the plunger about a longitudinalaxis of the plunger during the moving. The plunger is then moved in adistal direction within the volume of the syringe body to convey themedicament from the volume via the delivery tip.

The term “about” when used in connection with a referenced numericindication means the referenced numeric indication plus or minus up to10 percent of that referenced numeric indication. For example, “about100” means from 90 to 110.

As used in this specification and the appended claims, the words“proximal” and “distal” refer to direction closer to and away from,respectively, an operator of the medical device. Thus, for example, theend of the syringe assembly contacting the patient's body (e.g., beinginserted into the mouth, supporting a needle, or the like) would be thedistal end of the syringe assembly, while the end opposite the distalend would be the proximal end of the syringe assembly.

As used in this specification and the appended claims, the term“medicament” includes any constituent of a therapeutic substance. Amedicament can include such constituents regardless of their state ofmatter (e.g., solid, liquid or gas). Moreover, a medicament can includethe multiple constituents that can be included in a therapeuticsubstance in a mixed state, in an unmixed state and/or in a partiallymixed state. A medicament can include both the active constituents andinert constituents of a therapeutic substance. Accordingly, as usedherein, a medicament can include non-active constituents such as, water,colorant or the like.

The term “fluid-tight” is understood to encompass hermetic sealing(i.e., a seal that is gas-impervious) as well as a seal that is onlyliquid-impervious. The term “substantially” when used in connection with“fluid-tight,” “gas-impervious,” and/or “liquid-impervious” is intendedto convey that, while total fluid imperviousness is desirable, someminimal leakage due to manufacturing tolerances, or other practicalconsiderations (such as, for example, the pressure applied to the sealand/or within the fluid), can occur even in a “substantiallyfluid-tight” seal. Thus, a “substantially fluid-tight” seal includes aseal that prevents the passage of a fluid (including gases, liquidsand/or slurries) therethrough when the seal is maintained at pressuresof less than about 5 psig, less than about 10 psig, less than about 20psig, less than about 30 psig, less than about 50 psig, less than about75 psig, less than about 100 psig, and all values in between. Anyresidual fluid layer that may be present on a portion of a wall of acontainer after component defining a “substantially-fluid tight” sealare moved past the portion of the wall are not considered as leakage.

The term “opaque” is understood to include structures (such as portionsof a syringe body) that are not transparent and/or that do not permit anobject to be clearly or distinctly seen through the structure. The term“opaque” or “substantially opaque” or “semi-opaque” when used inconnection with the description of a side wall of a syringe body or anyother structure described herein is intended to convey that objectscannot be clearly seen through the side wall. A side wall (or portionthereof) described as being “opaque” or “substantially opaque” or“semi-opaque” is understood to include structures that may have ablocking color, or that may not have a color, but that are otherwisehazy, blurry, smeared, textured or the like.

FIGS. 1-4 are schematic illustrations of a syringe assembly 100according to an embodiment that includes a syringe body 110 and aplunger 140. FIG. 1 shows an exploded view of the syringe assembly 100to illustrate the syringe body 110 and the plunger 140. FIGS. 2-4 showthe syringe assembly 100 in a first, second, and third configuration,respectively. The syringe body 110 includes a side wall 115, and definesan interior volume 118 within which a medicament can be contained. Thesyringe body 110 includes a proximal end portion 112 having anengagement portion 124, and defines a longitudinal axis L_(A). Theengagement portion 124 can be any suitable structure or mechanism toengage and/or interface with a corresponding engagement portion of theplunger 140 to limit rotation of the plunger 140 within the syringe body110 about the longitudinal axis L_(A). For example, in some embodiments,the engagement portion 124 can include a protrusion configured to bedisposed within a corresponding groove of the plunger 140. In otherembodiments, the engagement portion 124 can include a recessed portionconfigured to receive a protrusion of the plunger 140. In yet otherembodiments, the engagement portion 124 can include a splined surfacethat interfaces with a corresponding splined surface of the plunger 140to limit, reduce and/or prevent rotation of the plunger 140 within thesyringe body 110.

The syringe body 110 includes a distal end portion 114 having a deliverytip 132. The delivery tip 132 can be any suitable tip or member throughwhich the medicament can be conveyed either into or out of the volume118 of the syringe body 110. In some embodiments, the delivery tip 132can be a protrusion extending from the syringe body 110 that can bereceived within a medicament container (e.g., bottle, vial or the like)and that can also deliver the medicament orally to the patient. In otherembodiments, the delivery tip 132 can a tapered fitting (such as a Luerfitting) that is adapted to couple the distal end portion 114 of thesyringe body 110 to a needle (not shown).

The syringe body 110 includes a transparent window 116. As described inmore detail below, the transparent window 116 is positioned such that atleast one indicia 146 on the plunger 140 is visible therethrough. Thetransparent window 116 can be of any suitable size and/or shape to allowvisual access to the indicia 146. Thus, although the transparent window116 is shown as being rectangular, in other embodiments, the transparentwindow 116 (and any of the transparent windows shown and describedherein) can be any shape, such circular, triangular, elliptical or thelike. In some embodiments, the transparent window is sized such thatonly one indicia from the set of indicia 146 is visible through thetransparent window 116 at a time. In some embodiments, a portion of theside wall 115 surrounding the transparent window 116 is opaque (orsemi-opaque), thereby “framing” or accentuating the window 116. In thismanner, during use, the indicia displayed within the transparent window116 are clearly accentuated to the user. In some embodiments, forexample, the side wall 115 of the syringe body 110 can include markings(e.g., thick lines, colors or the like) to highlight the transparentwindow 116.

In some embodiments, the syringe body 110 (or any of the syringe bodiesshown and described herein) includes an opaque or semi-opaque label (notshown in FIGS. 1-4) that is coupled to at least a portion of the syringebody 110. The opaque label can define an opening that is aligned withand/or that defines the transparent window 116 of the syringe body 110.In such embodiments, the opaque label can include markings to highlightand/or “frame” the transparent window 116. Moreover, the opaque labelcan include instructions or other indicia associated with themedicament, therapeutic regimen or the like. For example, in someembodiments, an opaque label can include markings such as “weight,” “day1,” and/or the drug name.

In some embodiments, the syringe body the syringe body can beconstructed from a clear material (e.g., plastic or glass), and thesyringe body 110 can include an opaque label that defines thetransparent window 116. In other embodiments, the syringe body caninclude a monolithically constructed opaque or semi-opaque portion. Suchportions can include a light blocking color, or can be devoid of color,but can otherwise by hazy, blurred or textured to prevent medicamentinside of the syringe body from being clearly seen.

The plunger 140 includes a proximal end portion 142 and a distal endportion 144 and defines a longitudinal axis L_(A). The distal endportion 144 is configured to move within the interior volume 118 thesyringe body 110 to convey a medicament 105. More particularly, asdescribed in more detail below, the distal end portion 144 canreciprocate within the syringe body 110 along the longitudinal axisL_(A) to convey the medicament 105 into the volume 118 (as shown by thearrow BB in FIG. 3), and convey the medicament 105 out of the volume 118(as shown by the arrow DD in FIG. 4). In some embodiments, the distalend portion 144 includes an elastomeric member defining a fluid-tight(or substantially fluid-tight) seal with the side wall 115 of thesyringe body 110.

The plunger 140 includes an engagement portion 148 configured tointerface with the engagement portion 124 of the syringe body 110 tolimit rotation of the plunger 140 about its longitudinal axis L_(A). Theengagement portion 148 can be any suitable structure or mechanism toengage and/or interface with the engagement portion 124 of the syringebody 110 to limit rotation of the plunger 140 within the syringe body110 about the longitudinal axis L_(A). For example, in some embodiments,the engagement portion 148 can include a protrusion configured to bedisposed within a corresponding groove of the syringe body 110. In otherembodiments, the engagement portion 148 can include a recessed portionconfigured to receive a protrusion of the syringe body 110. In yet otherembodiments, the engagement portion 148 can include a splined surfacethat interfaces with a corresponding splined surface of the syringe body110 to limit, reduce and/or prevent rotation of the plunger 140 withinthe syringe body 110

The plunger 140 includes an outer surface 145 having a series of indicia146. As shown in FIGS. 3 and 4, at least one of the indicia from theseries of indicia 146 is visible through the transparent window 116 ofthe syringe body 110. In this manner, the indicia 146 can provide avisual indication of the dosage of medicament 105 drawn into the syringebody 110. More specifically, because the indicia 146 are in a fixedposition on the plunger 140 and the transparent window 116 is in a fixedposition on the syringe body 110, the position of the plunger 140 withinthe syringe body 110 at which one of the indicia 146 is visible via thetransparent window 116 corresponds to a particular volume (i.e., dosagevolume) within the syringe body 110. In some embodiments, however, theindicia 146 can be non-volumetric indicia that correspond to acharacteristic of the patient. For example, in some embodiments, theindicia 146 can correspond to a weight, height, age, target body weight,and/or body mass index (BMI) of the patient. In other embodiments, theindicia 146 can correspond to a test result associated with the patient,including, for example, a range of blood sugar (e.g., for insulindosage) or any other suitable test result. In this manner, a user canwithdraw a dosage of medicament without the need for calculation orconversion to determine the volumetric amount.

In some embodiments, the series of indicia 146 can include both a seriesof dosage amounts (e.g., a series of weight ranges corresponding thedesired dosage) and one or more instructions. For example, in someembodiments, one indicia from the series of indicia 146 can beconfigured and/or position to be visible via (or appear within) thetransparent window 116 when the syringe assembly 100 is in a “ready” (orempty) state. This is shown, for example, in FIG. 2 (the syringeassembly 100 in the first configuration), which shows the indicia YY asbeing visible via the transparent window 116 when the plunger 140 is inthe distal-most position within the syringe body 110. In someembodiments, an instruction indicia 146 can include an identification ofthe drug with which the syringe assembly 100 should be used. In thismanner, the instruction indicia 146 can minimize the likelihood that thesyringe assembly 100 will be used with an improper medicament.

The series of indicia 146 can be arranged along the outer surface 145 inany suitable manner or orientation. For example, in some embodiments,the series of indicia 146 is arranged coaxially along the longitudinalaxis L_(A). In this manner, when the plunger 140 is reciprocated alongthe longitudinal axis L_(A) within the internal volume 118 of thesyringe body 110, each of the indicia 146 will be visible through thetransparent window 116 at given plunger position.

In use, the distal end portion 144 of the plunger 140 can bereciprocated within the syringe body 110 along the longitudinal axisA_(L) to convey a medicament 105 into and/or out of the internal volume118 of the syringe body 110. FIG. 2 shows the syringe assembly 100 inits initial or “ready” configuration. In the initial configuration, theplunger 140 is positioned at its distal-most position within the syringebody 110. In the initial configuration, a first indicia 146 (the indicia“YY”) is shown as being visible through the transparent window 146. Thefirst indicia 146 (indicated as “YY”) can be, for example, aninstruction indicia, a warning, a drug label, or the like. Although thefirst indicia 146 (the indicia “YY”) is shown as being visible throughthe transparent window 146 when the syringe assembly 100 is in itsinitial configuration, in other embodiments, no indicia is viewablethrough the transparent window 116 when the syringe assembly 100 is inits first configuration.

To prepare a dose of the medicament 105 for delivery, the delivery tip132 is placed in fluid communication with a source of medicament (e.g.,a medicament container, not shown in FIGS. 1-4), and the plunger 140 ismoved proximally, as shown by the arrow AA in FIG. 3. The movement ofthe distal end portion 144 of the plunger 140 within the syringe body110 increases the internal volume 118, which, in turn, produces a vacuumthat draws the medicament 105 into the syringe body 110 as shown by thearrow BB in FIG. 3. As shown in FIG. 3, the plunger 140 is movedproximally until a second indicia 146 (the indicia “XXX”) is visiblethrough a transparent window 116. In this manner, the syringe assembly100 is placed in its second (or “dosage set”) configuration. The secondindicia 146 (indicated as “XXX”) can be, for example, a dose indicia. Insome embodiments, the second indicia 146 can be a non-volumetric indicia(e.g., a weight range, a height range and/or an age range of thepatient). In this manner, the user can easily set the desired dosage bywithdrawing the plunger 140 until the second indicia 146 (the indicia“XXX”) is visible within the transparent window 116. This arrangementallows the dosage to be set without the need for calculation, conversionor consideration of the patient's characteristics to a volumetricmeasurement.

In some embodiments, the side wall 115 of the syringe body 110 includesa syringe detent (not shown in FIGS. 1-4) configured to engage one ormore plunger detents (not shown in FIGS. 1-4) to resist movement of thedistal end portion 144 of the plunger 140 within the syringe body 110when each of the series of indicia 146 is visible through thetransparent window. In this manner, the user can receive a tactilesensation (e.g., a slight snap, click or vibration) when each of theindicia 146 are aligned with and/or visible via the transparent window116. In this manner, the syringe assembly 100 can allow for a series ofdiscrete intervals of plunger movement within the syringe body 110.

As described above, during the movement of the plunger 140, theengagement portion 148 of the plunger 140 interfaces with the engagementportion 124 of the syringe body 110 to limit rotation of the plunger 140about a longitudinal axis L_(A) of the plunger. In this manner, theindicia 146 remain radially aligned with the transparent window 116,thus ensuring that the indicia 146 will be visible through thetransparent window 116 when the plunger 140 is in the correspondinglongitudinal position within the syringe body 110.

Although shown as having only two indicia 146, in other embodiments, theouter surface 145 of the plunger 140 can include any number of indicia146. For example, in some embodiments, the plunger 140 can include aseries of indicia 146 corresponding to the following weight ranges ofthe patient: 12 to 17 pounds, 18 to 23 pounds, 24 to 35 pounds, 36 to 47pounds, 48 to 60 pounds, 61 to 75 pounds, 76 to 90 pounds, and greaterthan 90 pounds. In other embodiments, the plunger 140 can include aseries of indicia 146 corresponding to the following age ranges of thepatient: 6 to 18 months, 18 months to 3 years, 3 to 5 years, 6 to 11years, and 12 years and higher. In yet other embodiments, the plunger140 can include a series of indicia 146 that do not correspond to ranges(e.g., they may correspond to a specific weight, age, height, lab testresult or the like). Such indicia may include for example, ametric/English marking (10 lb/4.5 kg).

Although shown as having a series of indicia 146 arranged longitudinallyalong the plunger 140, in other embodiments, the plunger can alsoinclude an indicia (e.g., an instruction indicia, a warning or the like)on the proximal end portion that is exposed from the syringe body 110when the syringe assembly 100 is in its first configuration. Forexample, in some embodiments, the plunger 140 can include an indicia(not shown in FIGS. 1-4) facing outwardly from the activation surface152 or “handle” of the plunger 140.

To deliver the dosage withdrawn, the user then places the delivery tip132 in the desired location (e.g., in the patient's mouth) and moves theplunger 140 distally, as shown by the arrow CC in FIG. 4. The movementof the distal end portion 144 of the plunger 140 within the syringe body110 decreases the internal volume 118, which, in turn, produces apressure that conveys the medicament 105 out of the syringe body 110 asshown by the arrow DD in FIG. 4. This movement places the syringeassembly 100 in its third (or dose delivered) configuration.

In some embodiments, the syringe assembly 100 can be cleaned for reuseby repeatedly reciprocating the plunger 140 within the syringe body 110to rinse with water, saline solution or the like. In other embodiments,the syringe assembly 100 can be disassembled for cleaning (e.g., bydecoupling the engagement portion 148 of the plunger 140 from theengagement portion 124 of the syringe body 110.

The syringe body 110 and any of the syringe bodies shown and describedherein can be constructed of any suitable material, such as hard plasticor glass. In some embodiments, the syringe body 110, or any of thesyringe bodies described herein, can be constructed from moldableplastic materials such as, for example, a polymeric plastic including,but not limited to, polyethylene, polypropylene, polycarbonate,polytetrafluoroethylene (PTFE), a phenol formaldehyde resin (e.g.,Bakelite) and/or the like. In some embodiments, the syringe body 110, orany of the syringe bodies shown and described herein, is monolithicallyconstructed. For example, the syringe body 110 and any of the syringebodies shown and described herein can be molded to form a singlecomponent having a constant cross-sectional diameter. In otherembodiments, however, the syringe body 110, and any of the syringebodies shown and described herein, can be constructed from multipleseparate components that are later joined together.

The plunger 140 and any of the plungers shown and described herein canbe constructed of any suitable material, such as hard plastic. In someembodiments, the plunger 140, or any of the plungers described herein,can be constructed from moldable plastic materials such as, for example,a polymeric plastic including, but not limited to, polyethylene,polypropylene, polycarbonate, polytetrafluoroethylene (PTFE), a phenolformaldehyde resin (e.g., Bakelite) and/or the like. In someembodiments, the plunger 140, or any of the plungers shown and describedherein, is monolithically constructed. In other embodiments, however,the plunger 140, and any of the plungers shown and described herein, canbe constructed from multiple separate components that are later joinedtogether. For example, in some embodiments, the plunger 140 can includea hard plastic member and an elastomeric member (not identified in FIGS.1-4) that seals the medicament 105 within the volume 118. In suchembodiments, the elastomeric member can be of any design or formulationsuitable for contact with the medicament 105.

In some embodiments, a syringe body can include a flange (eithermonolithically formed along with the remainder of the syringe body orformed separately and later coupled to the remainder of the syringebody). For example, FIGS. 5-7 show a syringe assembly 200 according toan embodiment that includes a syringe body 210 and a plunger 240. Thesyringe body 210 includes a side wall 215, and defines an interiorvolume within which a medicament can be contained. The syringe body 210includes a proximal end portion 212 and a distal end portion 214, anddefines a longitudinal axis (not identified in FIGS. 5-7). The distalend portion 214 has a delivery tip 232. The delivery tip 232 can be anysuitable tip or member through which the medicament can be conveyedeither into or out of the syringe body 210.

The proximal end portion 212 includes a flange 222 that can bemanipulated by a user to move the plunger 240 within the syringe body210. As shown in FIG. 7, the flange 222 includes an engagementprotrusion 224 that is disposed within and/or interfaces with acorresponding engagement groove 248 of the plunger 240 to limit rotationof the plunger 240 within the syringe body 210 about the longitudinalaxis. In this manner, as discussed below, the series of indicia 246 onthe plunger 240 remain in a constant radial position relative to thesyringe body 210 during use.

As shown in FIG. 7, the syringe body 210 includes an opaque (orsemi-opaque) portion 220 and a transparent portion 221. The transparentportion 221 can extend the length of the syringe body 210, and can allowa user to visually inspect the medicament withdrawn into the syringebody 210. For example, by visually inspecting the medicament via thetransparent portion 221, a user can verify that the medicament was fullywithdrawn into the syringe body 210 (as opposed to withdrawing asignificant amount of air), can evaluate the status of the medicament orthe like. Moreover, in some embodiments, the transparent portion 221 caninclude graduated markings to allow the user to verify the volume ofmedicament conveyed into the syringe.

The syringe body further includes a transparent window 216 within theopaque portion 220. As described in more detail below, the transparentwindow 216 is positioned such that at least one indicia 246 on theplunger 240 is visible via the transparent window 216. The transparentwindow 216 can be of any suitable size and/or shape to allow visualaccess to the indicia 246. Thus, although the transparent window 216 isshown as being rectangular, in other embodiments, the transparent window216 (and any of the transparent windows shown and described herein) canbe any shape, such circular, triangular, elliptical or the like. Asshown in FIG. 6, the transparent window is sized such that only oneindicia from the set of indicia 246 is visible through the transparentwindow 216 at a time.

The opaque portion 220 of the syringe body 210 includes a visible frame211 that surrounds the transparent window 216. In this manner, duringuse, the indicia displayed within the transparent window 216 are clearlyaccentuated to the user. Although shown as being a solid rectangular boxthat completely surrounds the transparent window 216, in otherembodiments, the visible frame 211 can be any pattern, and can onlypartially surround the transparent window. The opaque portion 220 of thesyringe body 210 includes instruction indicia 219. More specifically,the instruction indicia 219 include the characteristic of the patient tobe considered when setting the dosage (e.g., “child's weight”), and canalso include alignment marks or arrows. In other embodiments, theindicia 219 can include markings such as the identification of theregimen (e.g., “day 2”) and/or the drug name.

The plunger 240 includes a proximal end portion 242 and a distal endportion (not identified in FIGS. 5-7) that moves within the interiorvolume 218 the syringe body 210 to convey a medicament. Moreparticularly, as described in more detail below, the distal end portioncan reciprocate within the syringe body 210 along the longitudinal axisto convey the medicament into the syringe body 210 (to set a dosage),and convey the medicament out of the syringe body 210 (to deliver thedosage). The proximal end portion 242 of the plunger 240 includes anactuation flange 252 that can be grasped and/or manipulated by a user tomove the plunger 240 within the syringe body 210.

The plunger 240 includes an outer surface 245 having a series of indicia246. As shown in FIG. 6, at least one of the indicia from the series ofindicia 246 is visible through the transparent window 216 of the syringebody 210. In this manner, the indicia 246 can provide a visualindication of the dosage of medicament drawn into the syringe body 210.More specifically, because the indicia 246 are in a fixed position onthe plunger 240 and the transparent window 216 is in a fixed position onthe syringe body 210, the position of the plunger 240 within the syringebody 210 at which one of the indicia 246 is visible via the transparentwindow 216 corresponds to a particular volume (i.e., dosage volume)within the syringe body 210. As shown, the indicia 246 arenon-volumetric indicia that correspond to the patient's weight. Forexample, in some embodiments, the indicia 246 can correspond to aweight, height, age, target body weight, and/or body mass index (BMI) ofthe patient. In other embodiments, the indicia 246 can correspond to atest result associated with the patient, including, for example, a rangeof blood sugar (e.g., for insulin dosage) or any other suitable testresult. In this manner, a user can withdraw a dosage of medicamentwithout the need for calculation or conversion to determine thevolumetric amount.

As shown in FIG. 7, the plunger 240 includes an engagement groove 248configured to interface with the engagement protrusion 224 of thesyringe body 210 to limit rotation of the plunger 240 about itslongitudinal axis L_(A). The engagement groove 248 can be any suitableshape (e.g., rectangular, dovetail, or the like) to engage and/orinterface with the engagement protrusion 224 of the syringe body 210 tolimit rotation of the plunger 240 within the syringe body 210 about thelongitudinal axis L_(A). In this manner, the indicia 246 remain radiallyaligned with the transparent window 216, thus ensuring that the indicia246 will be visible through the transparent window 216 when the plunger240 is in the corresponding longitudinal position within the syringebody 210.

Although shown as including indicia 246 corresponding to specific weightranges, in other embodiments, the outer surface 245 of the plunger 240can include any number of indicia 246 covering any number of differentcharacteristics and/or ranges. For example, in some embodiments, theplunger 240 can include a series of indicia 246 corresponding to thefollowing age ranges of the patient: 6 to 28 months, 28 months to 3years, 3 to 5 years, 6 to 11 years, and 12 years and higher. In otherembodiments, the indicia 246 or any of the indicia described herein canbe associated with any characteristic, range and/or values describedherein. Although shown as having a series of indicia 246 arrangedlongitudinally along the plunger 240, in other embodiments, the plungercan also include an indicia (e.g., an instruction indicia, a warning orthe like) on the actuation surface 252 of the syringe body 210.

Although some of the syringe bodies are shown and described herein asbeing monolithically constructed, in other embodiments, a syringe bodycan include body portion that defines a medicament volume and a flangethat is separately constructed and affixed to the body portion. Forexample, FIGS. 8 and 9 show a portion of a syringe body 310 having aproximal end portion 312 that includes a flange 322. The flange 322 isseparately constructed and coupled to the syringe body 310, and can beincluded in any of the syringe bodies described herein. As shown, theflange 322 includes a proximal end portion 335 and a distal end portion336. The distal end portion 336 is coupled to the proximal end portion312 of the syringe body 310. The distal end portion 336 can be coupledto the syringe body 310 via any suitable mechanism, such as, forexample, by an interference (or “snap”) fit, a threaded connection, anadhesive joint, a weld, or the like.

The proximal end portion 335 of the flange 322 defines an engagementslot or groove 324 that receives and/or interfaces with a correspondingengagement protrusion of a plunger (not shown in FIGS. 8 and 9) to limitrotation of the plunger within the syringe body 310. In this manner, asdiscussed herein, any indicia or markings on the plunger can remain in aconstant radial position relative to the syringe body 310 during use.This arrangement ensures that the indicia will be visible through thetransparent window (not shown in FIGS. 8 and 9) of syringe body 310.

The proximal end portion 335 of the flange 322 also defines a lateralopening 337. The lateral opening 337 has a size and shape such that thedistal end portion of the plunger (not shown) can be removed from thesyringe body 310 via the lateral opening 337. Similarly stated, thelateral opening 337 is configured to allow the distal end portion of theplunger (including any elastomeric member coupled thereto) to passtherethrough. This arrangement allows for assembly and/or disassembly ofthe syringe assembly after the flange 322 is coupled to the syringe body310.

Although the syringe body 110 and the syringe body 210 are each shown asincluding a single transparent window (the transparent windows 116 and216, respectively), in other embodiments, a syringe body 110 can includeany number of transparent windows through which any number of differentplunger indicia can be viewed. For example, in some embodiments, asyringe body can include two transparent windows that are spaced apartfrom each other. Similarly stated, in some embodiments, a syringe bodycan include two transparent windows that are non-contiguous (e.g., thetwo transparent windows can be separated by an opaque portion or label).In such embodiments, a first plunger indicia can be visible through thefirst transparent window when the plunger is in a first position withinthe syringe body, and a second plunger indicia can be visible throughthe second transparent window when the plunger is in a second positionwithin the syringe body.

As one example of a syringe assembly having multiple transparentwindows, FIG. 10 shows a syringe assembly 400 that includes a plunger440 and a syringe body 410 having two transparent windows. The syringebody 410 includes a side wall, and defines an interior volume 418 withinwhich a medicament can be contained. The syringe body 410 includes aproximal end portion 412 and a distal end portion 414. The distal endportion 414 includes a delivery tip 432, which can be any suitable tipor member through which the medicament can be conveyed either into orout of the syringe body 410. In some embodiments, the delivery tip 432can be a protrusion extending from the syringe body 410 that can bereceived within a medicament container (e.g., bottle, vial or the like)and that can also deliver the medicament orally to the patient. In otherembodiments, the delivery tip 432 can a tapered fitting (such as a Luerfitting) that is adapted to couple the distal end portion 414 of thesyringe body 410 to a needle (not shown).

The syringe body 410 includes a first transparent window 416 and asecond transparent window 417. The first transparent window 416 and thesecond transparent window 417 are each positioned such that at least oneindicia 446 on the plunger 440 is visible therethrough when the plunger440 is in a particular longitudinal position within the syringe body 410(i.e., at a position that corresponds to a dosage). As shown, the outersurface of the syringe body 410 also includes a series of instructionindicia 419. The instruction indicia 419 are specific to and/or uniqueto each of the first transparent window 416 and the second transparentwindow 417. More specifically, the first transparent window 416 isadjacent to, framed by and/or associated with the instruction indicia419 indicating “DAY 1” and “Weight” and the second transparent window417 is adjacent to, framed by and/or associated with the instructionindicia 419 indicating “DAYS 2-5” and “Weight.” As described in moredetail below, this arrangement allows the syringe assembly 400 to easilyidentify the dosage of a drug for different days of a regimen thatspecifies different dosage amounts between the first day and the secondthrough fifth days. Such dosage regimens are common, for example, incertain antibiotic treatment regimens.

Although not shown in FIG. 10, the instruction indicia 419 can includeany other suitable characteristic of the patient to be considered whensetting the dosage (e.g., the patient's height, age, target body weight,body mass index, test results, blood sugar range, and/or a severityindex associated with a disease or condition), and can also includealignment marks or arrows.

In some embodiments, the syringe body 410 (or any of the syringe bodiesshown and described herein) includes an opaque (or semi-opaque) label(not shown in FIG. 10) that is coupled to at least a portion of thesyringe body 410. The opaque label can define an opening that is alignedwith and/or that defines the first transparent window 416 and/or thesecond transparent window 417. In such embodiments, the opaque label caninclude the instruction indicia 419 and/or markings to highlight and/or“frame” the first transparent window 416 and/or the second transparentwindow 417.

The first transparent window 416 and/or the second transparent window417 can be of any suitable size and/or shape to allow visual access tothe indicia 446. Thus, although the first transparent window 416 and thesecond transparent window 417 are shown as being rectangular, in otherembodiments, the first transparent window 416 and/or the secondtransparent window 417 (and any of the transparent windows shown anddescribed herein) can be any shape, such circular, triangular,elliptical or the like. In some embodiments, the first transparentwindow 416 and/or the second transparent window 417 are sized such thatonly one indicia from the set of indicia 446 is visible through therespective transparent window at a time.

The plunger 440 includes a proximal end portion 442 and a distal endportion (not labeled in FIG. 10) that moves within the interior volume418 the syringe body 410 to convey a medicament. More particularly, asdescribed in more detail below, the plunger 440 can reciprocate alongits longitudinal axis within the syringe body 410 to convey themedicament into the volume 418 (to set a dosage), and convey themedicament out of the volume 418 (to deliver the dosage). In someembodiments, the distal end portion of the plunger 440 includes anelastomeric member defining a fluid-tight (or substantially fluid-tight)seal with the side wall of the syringe body 410.

An outer surface of the plunger 440 includes at least one indicia 446(identified as XXX). As shown, the indicia 446 is visible through eachof the first transparent window 416 and the second transparent window417 of the syringe body 410. In this manner, the indicia 446 can providea visual indication of the dosage of medicament drawn into the syringebody 410. More specifically, because the indicia 446 is in a fixedposition on the plunger 440 and each of the first transparent window 416and the second transparent window 417 is in a fixed position on thesyringe body 410, the position of the plunger 440 within the syringebody 410 at which the indicia 446 is visible via the respectivetransparent window corresponds to a particular volume (i.e., dosagevolume) within the syringe body 410. In some embodiments, however, theindicia 446 can be non-volumetric indicia that correspond to acharacteristic of the patient. For example, in some embodiments, theindicia 446 can correspond to a weight, height, age, target body weight,and/or body mass index (BMI) of the patient. In other embodiments, theindicia 446 can correspond to a test result associated with the patient,including, for example, a range of blood sugar (e.g., for insulindosage) or any other suitable test result. In this manner, a user canwithdraw a dosage of medicament without the need for calculation orconversion to determine the volumetric amount.

In use, the plunger 440 can be reciprocated within the syringe body 410along the longitudinal axis to convey a medicament into and/or out ofthe internal volume 418 of the syringe body 410. To prepare a dose ofthe medicament for delivery on the first day of the regimen, thedelivery tip 432 is placed in fluid communication with a source ofmedicament (e.g., a medicament container, not shown in FIG. 10), and theplunger 440 is moved proximally to draw the medicament into the syringebody 410. The plunger 440 is moved proximally until the indicia 446 (theindicia “XXX”) is visible through the first transparent window 416. Inthis manner, the syringe assembly 400 is placed in its second (or “day113 dosage set”) configuration. The indicia 446 (indicated as “XXX”) canbe, for example, a non-volumetric indicia (e.g., a weight range, aheight range and/or an age range of the patient). In this manner, theuser can easily set the desired dosage for a particular day of a regimenby withdrawing the plunger 440 until the indicia 446 (the indicia “XXX”)is visible within the desired transparent window. This arrangementallows the dosage to be set without the need for calculation, conversionor consideration of the patient's characteristics to a volumetricmeasurement.

To deliver the dosage withdrawn, the user then places the delivery tip432 in the desired location (e.g., in the patient's mouth) and moves theplunger 440 distally. The movement of the distal end portion of theplunger 440 within the syringe body 410 decreases the internal volume418, which, in turn, produces a pressure that conveys the medicament outof the syringe body 410.

To prepare a dose of the medicament for delivery on the second throughfifth days of the regimen, the delivery tip 432 is again placed in fluidcommunication with the source of medicament, and the plunger 440 ismoved proximally to draw the medicament into the syringe body 410. Theplunger 440 is moved proximally until the indicia 446 (the indicia“XXX”) is visible through the second transparent window 417. In thismanner, the syringe assembly 400 is placed in its second (or “days2-5—dosage set”) configuration. The dosage can then be delivered asdescribed above.

Although the syringe body 410 is described as including at least twotransparent windows arranged coaxially along a longitudinal axis, inother embodiments, a syringe body can include any number of transparentwindows arranged in any manner along the syringe body. For example,FIGS. 11 and 12 show a syringe assembly 500 that includes a plunger 540,a syringe body 510 having multiple transparent windows, and a series ofremovable labels. The syringe body 510 includes a proximal end portion512 and a distal end portion 514. The distal end portion 514 includes adelivery tip 532, which can be any suitable tip or member through whichthe medicament can be conveyed either into or out of the syringe body510. In some embodiments, the delivery tip 532 can be a protrusionextending from the syringe body 510 that can be received within amedicament container (e.g., bottle, vial or the like) and that can alsodeliver the medicament orally to the patient. In other embodiments, thedelivery tip 532 can a tapered fitting (such as a Luer fitting) that isadapted to couple the distal end portion 514 of the syringe body 510 toa needle (not shown).

The syringe body 510 includes a first transparent window 516, a secondtransparent window 517, and a third transparent window 518 (which iscovered by the removable label 530). The first transparent window 516,the second transparent window 517, and the third transparent window 518are positioned offset from each other along the longitudinal axis of thesyringe body 510. Moreover, each of the transparent windows ispositioned such that at least one indicia 546 on the plunger 540 isvisible therethrough when the plunger 540 is in a particularlongitudinal position within the syringe body 510 (i.e., at a positionthat corresponds to a dosage). Although FIG. 12 only shows one indicia546, which is visible via the second transparent window 517, the plunger540 includes a series of indicia 546 (not shown) that are radiallyaligned with each of the first transparent window 516 and the thirdtransparent window 518.

As shown, the outer surface of the syringe body 510 also includes aseries of instruction indicia 519. At least portion of the instructionindicia 519 are specific to and/or unique to each of the firsttransparent window 516, the second transparent window 517, and the thirdtransparent window 518. More specifically, the first transparent window516 is adjacent to, framed by and/or associated with the instructionindicia 519 indicating “DAY 1” and “LB” and the second transparentwindow 517 is adjacent to, framed by and/or associated with theinstruction indicia 519 indicating “DAY 2” and “LB” (portions of “DAY 2”are not shown in FIG. 12). As described in more detail below, thisarrangement allows the syringe assembly 500 to easily identify thedosage of a drug for different days of a regimen. Although not shown inFIGS. 11 and 12, the instruction indicia 519 can include any othersuitable characteristic of the patient to be considered when setting thedosage (e.g., the patient's height, age, target body weight, body massindex, blood sugar range and/or a severity index associated with adisease or condition), and can also include alignment marks or arrows.

In some embodiments, the syringe body 510 (or any of the syringe bodiesshown and described herein) includes an opaque (or semi-opaque) label(not shown in FIGS. 11 and 12) that is coupled to at least a portion ofthe syringe body 510. The opaque label can define an opening that isaligned with and/or that defines the first transparent window 516, thesecond transparent window 517, and/or the third transparent window 518.In such embodiments, the opaque label can include the instructionindicia 519 and/or markings to highlight and/or “frame” the firsttransparent window 516 and/or the second transparent window 517. Theopaque label can also surround only a portion of the syringe body 510,thereby allowing a portion of the syringe body 510 to remain transparent(e.g., for viewing the medicament within the syringe body 510).

The first transparent window 516, the second transparent window 517,and/or the third transparent window 518 can be of any suitable sizeand/or shape to allow visual access to the indicia 546. Thus, althoughthe first transparent window 516, the second transparent window 517, andthe third transparent window 518 are shown as being rectangular, inother embodiments, the first transparent window 516, the secondtransparent window 517, and/or the third transparent window 518 (and anyof the transparent windows shown and described herein) can be any shape,such circular, triangular, elliptical or the like. In some embodiments,the first transparent window 516, the second transparent window 517,and/or the third transparent window 518 are sized such that only oneindicia from the set of indicia 546 is visible through the respectivetransparent window at a time.

As shown in FIG. 11, each of the transparent windows is initiallycovered by a removable label. More particularly, the first transparentwindow 516 is covered by a first removable label 528, the secondtransparent window 517 is covered by a second removable label 529, andthe third transparent window 518 is covered by a third removable label530. Each of the removable labels includes a unique instruction indicia(e.g., “Day 1,” “Day 2,” and “Day 3”). Each of the removable labels canbe attached to the syringe body 510 (and/or any opaque label coupledthereto) by any suitable mechanism, such as, for example, by anadhesive, a perforated joint, or the like.

The plunger 540 includes a proximal end portion 542 and a distal endportion (not labeled in FIGS. 11 and 12) that moves within the syringebody 510 to convey a medicament. More particularly, as described in moredetail below, the plunger 540 can reciprocate along its longitudinalaxis within the syringe body 510 to convey the medicament into thesyringe body 510 (to set a dosage), and convey the medicament out of thesyringe body 510 (to deliver the dosage). In some embodiments, thedistal end portion of the plunger 540 includes an elastomeric memberdefining a fluid-tight (or substantially fluid-tight) seal with the sidewall of the syringe body 510.

The outer surface of the plunger 540 includes a series of indicia 546(only one indicia, identified as XX, is shown in FIG. 12). As shown, atleast a subset of the indicia 546 is visible through the firsttransparent window 516, the second transparent window 517, and the thirdtransparent window 518. For example, in some embodiments, the plunger540 can include three different subsets of indicia 546 that are spacedlongitudinally and/or radially apart from each other. Each of the threesubsets of indicia can be longitudinally and/or radially aligned with acorresponding transparent window. In this manner, the indicia 546 canprovide a visual indication of the dosage of medicament drawn into thesyringe body 510 for each specific day of a therapeutic regimen. Morespecifically, each indicia 546 is in a fixed position on the plunger540, and each of the first transparent window 516, the secondtransparent window 517, and the third transparent window 518 is in afixed position on the syringe body 510, the position of the plunger 540within the syringe body 510 at which the indicia 546 is visible via therespective transparent window corresponds to a particular volume (i.e.,dosage volume) within the syringe body 510. In some embodiments, theindicia 546 can be non-volumetric indicia that correspond to acharacteristic of the patient. For example, in some embodiments, theindicia 446 can correspond to a weight, height, age, target body weight,and/or body mass index (BMI) of the patient. In other embodiments, theindicia 446 can correspond to a test result associated with the patient,including, for example, a range of blood sugar (e.g., for insulindosage) or any other suitable test result. In this manner, a user canwithdraw a dosage of medicament without the need for calculation orconversion to determine the volumetric amount.

In use, the plunger 540 can be reciprocated within the syringe body 510along the longitudinal axis to convey a medicament into and/or out ofthe internal volume 518 of the syringe body 510. To prepare a dose ofthe medicament for delivery on the first day of the regimen, the firstremovable label 528 is removed from the syringe body 510, as shown bythe arrow EE in FIG. 11. The indicia on the first removable label 528(“Day 1”) provides a reminder to the user that the current dosage to beadministered is the first day dosage. After the first removable label528 is removed, the first transparent window 516 is visible to allow forconvenient dosing of the “Day 1” medicament.

The delivery tip 532 is placed in fluid communication with a source ofmedicament (e.g., a medicament container, not shown in FIGS. 11 and 12),and the plunger 540 is moved proximally to draw the medicament into thesyringe body 510. The plunger 540 is moved proximally until the desiredindicia 546 is visible through the first transparent window 516. In thismanner, the syringe assembly 500 is placed in its second (or “day1—dosage set”) configuration (this configuration is not shown in FIGS.11 and 12). The indicia 546 can be, for example, a non-volumetricindicia (e.g., the patient's height, age, target body weight, body massindex, blood sugar range and/or a severity index associated with adisease or condition). In this manner, the user can easily set thedesired dosage for the first day of a regimen by withdrawing the plunger540 until the desired indicia 546 is visible within the desiredtransparent window. To deliver the dosage withdrawn, the user thenplaces the delivery tip 532 in the desired location (e.g., in thepatient's mouth) and moves the plunger 540 distally. The movement of thedistal end portion of the plunger 540 within the syringe body 510decreases the internal volume 518, which, in turn, produces a pressurethat conveys the medicament out of the syringe body 510.

To prepare a dose of the medicament for delivery on the second day ofthe regimen, the second removable label 529 is removed from the syringebody 510. The indicia on the second removable label 529 (“Day 2”)provides a reminder to the user that the current dosage to beadministered is the second day dosage. After the second removable label529 is removed, the second transparent window 517 is visible. Thedelivery tip 532 is again placed in fluid communication with the sourceof medicament, and the plunger 540 is moved proximally to draw themedicament into the syringe body 510. The plunger 540 is movedproximally until the desired indicia 546 (the indicia “XX” as shown inFIG. 12) is visible through the second transparent window 517. In thismanner, the syringe assembly 500 is placed in its third (or “day2—dosage set”) configuration, as shown in FIG. 12. The dosage can thenbe delivered as described above.

This process is repeated for the third day dosage. Upon removal of thethird (or last) removable label 530 and delivery of the third daydosage, the user can then discard the syringe assembly 500. In someembodiments, the syringe body 510 can include an instruction indiciathat is revealed after removal of the third removable label 530instructing the user to discard the syringe assembly 500. Although thesyringe body 510 is shown as including only three transparent windows,in other embodiments, a syringe body can include any number oftransparent windows and/or removable labels corresponding to any numberof dosages, delivery days or the like.

In some embodiments, a syringe assembly can be used in conjunction withdifferent medicaments. Similarly stated, in some embodiments, a syringeassembly can include multiple sets of indicia, each of which correspondsto a different “scale” or dosage setting for a different drug. Forexample, FIG. 13 shows a syringe assembly 600 that includes a plunger640 and a syringe body 610 having two transparent windows, eachcorresponding to a different drug. The syringe body 610 includes aproximal end portion 612 and a distal end portion 614. The distal endportion 614 includes a delivery tip 632, which can be any suitable tipor member through which the medicament can be conveyed either into orout of the syringe body 610. In some embodiments, the delivery tip 632can be a protrusion extending from the syringe body 610 that can bereceived within a medicament container (e.g., bottle, vial or the like)and that can also deliver the medicament orally to the patient. In otherembodiments, the delivery tip 632 can a tapered fitting (such as a Luerfitting) that is adapted to couple the distal end portion 614 of thesyringe body 610 to a needle (not shown).

The syringe body 610 includes a first transparent window 616 and asecond transparent window 617. The first transparent window 616 and thesecond transparent window 617 are positioned offset from each otheralong the longitudinal axis of the syringe body 610, and each correspondto a different drug. Specifically, the first transparent window 616corresponds to “Drug 1” and the second transparent window 617corresponds to “Drug 2.” Moreover, the first transparent window 616 ispositioned such that at least one indicia from the first set of indicia646 (indicia W, X, Y and Z) on the plunger 640 is visible therethroughwhen the plunger 640 is in a particular longitudinal position within thesyringe body 610 (i.e., at a position that corresponds to a dosage). Thesecond transparent window 617 is positioned such that at least oneindicia from the second set of indicia 649 (indicia A, B and C) on theplunger 640 is visible therethrough when the plunger 640 is in aparticular longitudinal position within the syringe body 610 (i.e., at aposition that corresponds to a dosage).

As shown, the outer surface of the syringe body 610 also includes aseries of instruction indicia 619. At least portion of the instructionindicia 619 are specific to and/or unique to each of the firsttransparent window 616 and the second transparent window 617. Morespecifically, the first transparent window 616 is adjacent to, framed byand/or associated with the instruction indicia 619 indicating “Drug 1”and “Weight” and the second transparent window 617 is adjacent to,framed by and/or associated with the instruction indicia 619 indicating“Drug 2” and “Weight.” This arrangement allows the syringe assembly 600to easily identify the dosage for different drugs. Although not shown inFIG. 13, the instruction indicia 619 can include any other suitablecharacteristic of the patient to be considered when setting the dosage(e.g., the patient's height, age, target body weight, body mass index,blood sugar range and/or a severity index associated with a disease orcondition), and can also include alignment marks or arrows.

In some embodiments, the syringe body 610 (or any of the syringe bodiesshown and described herein) includes an opaque (or semi-opaque) label(not shown in FIG. 13) that is coupled to at least a portion of thesyringe body 610. The opaque label can define an opening that is alignedwith and/or that defines the first transparent window 616 and/or thesecond transparent window 617. In such embodiments, the opaque label caninclude the instruction indicia 619 and/or markings to highlight and/or“frame” the first transparent window 616 and/or the second transparentwindow 617. The opaque label can also surround only a portion of thesyringe body 610, thereby allowing a portion of the syringe body 610 toremain transparent (e.g., for viewing the medicament within the syringebody 610).

The first transparent window 616 and/or the second transparent window617 can be of any suitable size and/or shape to allow visual access tothe first set of indicia 646 and/or the second set of indicia 649,respectively. Thus, although the first transparent window 616 and thesecond transparent window 617 are shown as being rectangular, in otherembodiments, the first transparent window 616 and/or the secondtransparent window 617 can be any shape, such circular, triangular,elliptical or the like. In some embodiments, the first transparentwindow 616 and/or the second transparent window 617 are sized such thatonly one indicia from the first set of indicia 646 and/or the second setof indicia 649, respectively, is visible through the respectivetransparent window at a time.

The plunger 640 includes a proximal end portion 642 and a distal endportion (not labeled in FIG. 13) that moves within the syringe body 610to convey a medicament. The proximal end portion 642 of the plunger 640includes an actuation flange 652 that can be grasped and/or manipulatedby a user to move the plunger 640 within the syringe body 610. Asdescribed herein, the plunger 640 can reciprocate along its longitudinalaxis L_(A) within the syringe body 610 to convey the medicament into thesyringe body 610 (to set a dosage), and convey the medicament out of thesyringe body 610 (to deliver the dosage). The distal end portion of theplunger 640 includes an elastomeric member 658 defining a fluid-tight(or substantially fluid-tight) seal with the side wall of the syringebody 610.

The outer surface of the plunger 640 includes the first series ofindicia 646 (identified as W, X, Y and Z) and the second series ofindicia 649 (identified as A, B and C). As shown, the first series ofindicia 646 correspond to dosages of the first drug, and are visiblethrough the first transparent window 616. The second set of indicia 649correspond to dosages of the second drug, and are visible through thesecond transparent window 617. As shown, the first series of indicia 646is longitudinally and/or radially offset from the second series ofindicia 649.

In use, the first series of indicia 646 can provide a visual indicationof the dosage of medicament drawn into the syringe body 610 for thefirst drug, and the second series of indicia 649 can provide a visualindication of the dosage of medicament drawn into the syringe body 610for the second drug. More specifically, each indicia from the firstseries indicia 646 is in a fixed position on the plunger 640, and thefirst transparent window 616 is in a fixed position on the syringe body610. Thus, the position of the plunger 640 within the syringe body 610at which the one of the first series of indicia 646 is visible via thefirst transparent window 616 corresponds to a particular volume (i.e.,dosage volume) of the first drug within the syringe body 610. Similarly,each indicia from the second series indicia 649 is in a fixed positionon the plunger 640, and the second transparent window 617 is in a fixedposition on the syringe body 610. Thus, the position of the plunger 640within the syringe body 610 at which the one of the second series ofindicia 649 is visible via the second transparent window 617 correspondsto a particular volume (i.e., dosage volume) of the second drug withinthe syringe body 610

In some embodiments, the indicia 646, 649 can be non-volumetric indiciathat correspond to a characteristic of the patient. For example, in someembodiments, the indicia 646, 649 can correspond to a weight, height,age, target body weight, and/or body mass index (BMI) of the patient. Inother embodiments, the indicia 646, 649 can correspond to a test resultassociated with the patient, including, for example, a range of bloodsugar (e.g., for insulin dosage) or any other suitable test result. Inthis manner, a user can withdraw a dosage of medicament without the needfor calculation or conversion to determine the volumetric amount.

In some embodiments, a plunger and/or a syringe barrel can have anon-circular cross-sectional shape. In this manner, a dosage for a firstdrug (or day of a regimen) can be displayed on one side of a syringeassembly, and a dosage for a second drug (or day of a regimen) can bedisplayed on a second side of a syringe assembly. For example, FIG. 14shows a syringe assembly 700 that includes a plunger 740 and a syringebody 710 having a triangular cross-sectional shape. The syringe body 710includes a proximal end portion 712 and a distal end portion 714. Thedistal end portion 714 includes a delivery tip 732, which can be anysuitable tip or member through which the medicament can be conveyedeither into or out of the syringe body 710. In some embodiments, thedelivery tip 732 can be a protrusion extending from the syringe body 710that can be received within a medicament container (e.g., bottle, vialor the like) and that can also deliver the medicament orally to thepatient. In other embodiments, the delivery tip 732 can a taperedfitting (such as a Luer fitting) that is adapted to couple the distalend portion 714 of the syringe body 710 to a needle (not shown).

The syringe body 710 includes a first set of transparent windows 716 anda second set of transparent windows 717. The first set of transparentwindows 716 is positioned on a first side 713 of the syringe body 710,and the second set of transparent windows 717 is positioned on a secondside 715 of the syringe body 710. Although not shown in FIG. 14, thethird side of the syringe body 710 can include a third set oftransparent windows, can be fully transparent, or opaque (fully opaque,semi-opaque or otherwise configured to disrupt the clarity of viewingobjects therein). Each of the sets of transparent windows can correspondto a different drug, a different dosing regimen, or the like.Specifically, the first set of transparent windows 716 corresponds to“Drug 1” and the second set of transparent windows 717 corresponds to“Drug 2.” Moreover, the first set of transparent windows 716 ispositioned such that at least one indicia from the first set of indicia746 (indicia XXX, YYY, and ZZZ) on the plunger 740 is visible through atleast one of the first set of transparent windows 716 when the plunger740 is in a particular longitudinal position within the syringe body 710(i.e., at a position that corresponds to a dosage). The second set oftransparent window 717 is positioned such that at least one indicia fromthe second set of indicia 749 (indicia AAA, BBB and CCC) on the plunger740 is visible through at least one of the second set of transparentwindows 719 when the plunger 740 is in a particular longitudinalposition within the syringe body 710 (i.e., at a position thatcorresponds to a dosage).

As shown, the outer surface of the syringe body 710 also includes aseries of instruction indicia 719. At least portion of the instructionindicia 719 are specific to and/or unique to each of the first set oftransparent windows 716 and the second set of transparent windows 717.More specifically, the first set of transparent windows 716 is adjacentto, framed by and/or associated with the instruction indicia 719indicating “Drug 1” and the second set of transparent windows 717 isadjacent to, framed by and/or associated with the instruction indicia719 indicating “Drug 2.” This arrangement allows the syringe assembly700 to easily identify the dosage for different drugs.

The plunger 740 includes a proximal end portion 742 and a distal endportion (not labeled in FIG. 13) that moves within the syringe body 710to convey a medicament. The proximal end portion 742 of the plunger 740includes an actuation flange 752 that can be grasped and/or manipulatedby a user to move the plunger 740 within the syringe body 710. Asdescribed herein, the plunger 740 can reciprocate along its longitudinalaxis within the syringe body 710 to convey the medicament into thesyringe body 710 (to set a dosage), and convey the medicament out of thesyringe body 710 (to deliver the dosage). The distal end portion of theplunger 740 includes an elastomeric member 758 defining a fluid-tight(or substantially fluid-tight) seal with the side wall of the syringebody 710.

As shown, the plunger 740 has a triangular cross-sectional shape thatcorresponds to that of the syringe body 710. The non-circularcross-sectional shape of the plunger 740 limits rotation of the plungerabout a longitudinal axis of the plunger 740. A first side 743 of theplunger 740 includes the first series of indicia 746 (identified as XXX,YYY and ZZZ) and a second side 745 of the plunger 740 includes thesecond series of indicia 749 (identified as AAA, BBB and CCC). As shown,the first series of indicia 746 correspond to dosages of the first drug,and are visible through at least one window from the first set oftransparent windows 716. The second set of indicia 749 correspond todosages of the second drug, and are visible through at least one windowfrom the second set of transparent windows 717.

In use, the first series of indicia 746 can provide a visual indicationof the dosage of medicament drawn into the syringe body 710 for thefirst drug, and the second series of indicia 749 can provide a visualindication of the dosage of medicament drawn into the syringe body 710for the second drug. More specifically, each indicia from the firstseries indicia 746 is in a fixed position on the plunger 740, and thefirst transparent window 716 is in a fixed position on the syringe body710. Thus, the position of the plunger 740 within the syringe body 710at which the one of the first series of indicia 746 is visible via thefirst transparent window 716 corresponds to a particular volume (i.e.,dosage volume) of the first drug within the syringe body 710. Similarly,each indicia from the second series indicia 749 is in a fixed positionon the plunger 740, and the second transparent window 717 is in a fixedposition on the syringe body 710. Thus, the position of the plunger 740within the syringe body 710 at which the one of the second series ofindicia 749 is visible via the second transparent window 717 correspondsto a particular volume (i.e., dosage volume) of the second drug withinthe syringe body 710

In some embodiments, the indicia 746, 749 can be non-volumetric indiciathat correspond to a characteristic of the patient. For example, in someembodiments, the indicia 746, 749 can correspond to a weight, height,age, target body weight, and/or body mass index (BMI) of the patient. Inother embodiments, the indicia 746, 749 can correspond to a test resultassociated with the patient, including, for example, a range of bloodsugar (e.g., for insulin dosage) or any other suitable test result. Inthis manner, a user can withdraw a dosage of medicament without the needfor calculation or conversion to determine the volumetric amount.

In some embodiments, any of the syringe assemblies described herein canbe included within a kit that also contains a medicament container, alock member, a deliver member (e.g. a needle, an oral delivery tip, orthe like) associated packaging and/or an instruction set. For example,FIG. 15 is a schematic illustration of a kit 801 according to anembodiment that includes a syringe assembly 800 and a medicamentcontainer 802. The syringe assembly 800 can be similar to any of thesyringe assemblies shown and described herein. Accordingly, thestructure of the syringe assembly 800 (including any engagementportions, transparent windows, indicia, or the like) is not described indetail below.

As shown, the syringe assembly 800 includes a syringe body 810 and aplunger 840. The syringe body 810 is configured to contain a medicament(e.g., medicament 805 from the medicament container 802), and includes aproximal end portion 812 and a distal end portion. The proximal endportion 812 includes a flange, which can be similar to any of theflanges shown and described herein (e.g., the flange 222, the flange 322or any other flanges). The distal end portion 814 of the syringe body810 includes a delivery tip 832, which can be similar to any of thedelivery tips shown and described herein. In some embodiments, thedelivery tip 832 can be a separate piece that is attached to the distalend portion 814 of the syringe body 810. In such embodiments, the kit801 can include multiple different tips (e.g., for use on different daysof a regimen, for use with different delivery conditions or the like).

The syringe body 810 includes a first transparent window 816 and asecond transparent window. As described with reference to the othersyringe bodies disclosed herein, the first transparent window 816 ispositioned such that at least one indicia (not shown in FIG. 15) on theplunger 840 is visible therethrough. The first transparent window 816can be of any suitable size and/or shape to allow visual access to theindicia. The second transparent window 817 is positioned distally fromthe first transparent window 816, and can allow the user to view themedicament within the syringe body 810 after a dose has been set. Insome embodiments, for example, the second transparent window 817 extendsaround the entire circumference of the syringe body 810.

In some embodiments, the syringe body 810 includes an opaque (orsemi-opaque) portion or label (not shown in FIG. 15) that is coupled toat least a portion of the syringe body 810. The opaque label can definean opening that is aligned with and/or that defines the firsttransparent window 816 and/or the second transparent window 817. In suchembodiments, the opaque label can include markings to highlight and/or“frame” the first transparent window 816 and/or the second transparentwindow 817. Moreover, the opaque label can include instructions or otherindicia associated with the medicament, therapeutic regimen or the like.For example, in some embodiments, an opaque label can include markingssuch as “weight,” “day 1,” and/or the drug name.

The plunger 840 includes a distal end portion configured to move withinthe syringe body 810 to convey a medicament 805. More particularly, thedistal end portion 844 can reciprocate within the syringe body 810 alongthe longitudinal axis to convey the medicament 805 into the syringe body810 (to set a dosage), and convey the medicament 805 out of the syringebody 810 (to deliver the dosage). A proximal end portion of the plunger840 includes an actuation flange 852 that can be grasped and/ormanipulated by a user to move the plunger 840 within the syringe body810 to set and deliver a dose of the medicament 805, as describedherein.

The syringe assembly 800 includes a lock member 860 that is removablycoupled to the syringe body 810 and the plunger 840, and that limitsmovement of the plunger 840 within and/or with respect to the syringebody 810. In this manner, the lock member 860 can prevent the user fromactuating or using the syringe assembly 800. This arrangement can beuseful to provide instructions to the user regarding the particular drugor drugs with which the syringe assembly can be used. Said another way,the lock member 860 can reduce the likelihood that a user willimproperly use the syringe assembly 800 to administer a drug for whichit is not intended.

As shown, the lock member 860 includes a retention portion 861 thatdefines an opening 862. The opening 862 is configured to receive aportion of the flange 822 of the syringe body 810 and the actuationflange 852 of the plunger 840 to limit movement of the plunger 840 withrespect to the syringe body 810. In some embodiments, the retentionportion 861 is configured to produce an interference fit with the flange822 and the activation flange 852 when the syringe assembly 800 is in a“ready” (or first) configuration. The lock member 860 also includes aninstruction indicia 865 (“Drug 1 ONLY”) that warns the user regardingthe drugs and/or regimens for which the syringe assembly 800 should beused.

To prepare a dose of the medicament 805 for delivery, the cap is removedfrom the medicament container 802, and the lock member 860 is removedfrom the flange 822 and activation flange 852. The delivery tip 832 isplaced into the medicament container 802, and the plunger 840 is movedproximally. The proximal movement of the distal end portion of theplunger 840 within the syringe body 810 produces a vacuum that draws themedicament 805 from the container 802 into the syringe body 810. Theplunger 840 is moved proximally until an indicia on the plunger (notshown) is visible through the first transparent window 816. In thismanner, the syringe assembly 800 is placed in its second (or “dosageset”) configuration.

When the syringe assembly 800 is in the second configuration, themedicament within the syringe body 810 can be visually inspected via thesecond transparent window 817. To deliver the dosage withdrawn, the userthen places the delivery tip 832 in the desired location (e.g., in thepatient's mouth) and moves the plunger 840 distally, as describedherein. The movement of the distal end portion 844 of the plunger 840within the syringe body 810 produces a pressure that conveys themedicament 805 out of the syringe body.

In some embodiments, a kit can include features to reduce the likelihoodthat the syringe assembly therein will be used with a drug for which theassembly is not intended. For example, in some embodiments, a kit caninclude a coupling member that retains the syringe assembly to themedicament container. FIG. 16 shows a portion of a kit 901 according toan embodiment that includes a syringe assembly (not shown), a medicamentcontainer 902, and a lock member 960. The syringe assembly can besimilar to any of the syringe assemblies shown and described herein.Accordingly, the structure of the syringe assembly (including anyengagement portions, transparent windows, indicia, or the like) is notdescribed below. The medicament container 902 contains a medicament andincludes a removable cap 906.

The lock member 960 can be removably coupled to the syringe assembly tolimit actuation of the syringe assembly (e.g., movement of a plungerwithin a syringe body). In this manner, the lock member 960 can preventthe user from actuating or using the syringe assembly when the lockmember 960 is in place. As shown, the lock member 960 includes aretention portion 961 that defines an opening 962. The opening 962 isconfigured to receive a portion of the syringe assembly to limit and/orprevent actuation of the syringe assembly. In some embodiments, theretention portion 961 is configured to produce an interference fit withportions of the syringe assembly when the syringe assembly is in a“ready” (or first) configuration. The lock member 960 also includes aninstruction indicia 965 (“Drug 1 ONLY”) that warns the user regardingthe drugs and/or regimens for which the syringe assembly 900 should beused.

The lock member also includes a tether 968 that is coupled to the cap906 of the medicament container 902. In this manner, when the lockmember 960 is coupled to the syringe assembly, the syringe assembly willalso be attached to the medicament container 902. This arrangementmaintains the syringe assembly (not shown) and the medicament container902 in a coupled relationship, thereby reducing the likelihood that thesyringe body will be improperly used (e.g., with the wrong medicament).

Although shown as including a tether 968, in other embodiments, a kit, alock member and/or a syringe assembly can include any suitable mechanismfor coupling the syringe assembly to the medicament container. Forexample, in some embodiments, the lock member can include a rigid, “snapfit” member that couples a syringe body to a medicament container. Inother embodiments, a portion of a syringe body can also serve as the capfor a medicament container.

In some embodiments, a delivery tip of a syringe assembly can beuniquely configured to fit within an opening of a specific medicamentcontainer (e.g., the medicament container 802 or the medicamentcontainer 902). For example, as shown in FIGS. 17A and 17B, a deliverytip of a syringe assembly can be sized and/or shaped to fit within acorresponding opening of a medicament container. FIG. 17A shows asquare-shaped delivery tip 1032 of a syringe body 1010 that isconfigured to fit within a corresponding square-shaped opening of amedicament container (not shown). FIG. 17B shows a triangle-shapeddelivery tip 1032′ of a syringe body 1010′ that is configured to fitwithin a corresponding triangle-shaped opening of a medicament container(not shown).

FIG. 18 is a flow chart illustrating a method 10 of setting a dose anddelivering a medicament, according to an embodiment. The method 10 canbe performed using any of the syringe assemblies or kits shown anddescribed herein. The method includes inserting a delivery tip of asyringe body into a medicament container, at 12. The delivery tip canbe, for example, an oral delivery tip (e.g., the tip 232 shown above, orany other delivery tips described herein). The medicament container canbe, for example, the medicament container 902 shown and described above.In some embodiments, the delivery tip can be shaped and/or sized to fitwithin a corresponding opening of the medicament container. In someembodiments, the method 10 optionally includes removing a lock member,such as the lock member 860 or the lock member 960, from the deliverytip to expose the tip before it is inserted into the medicamentcontainer.

A plunger is then moved in a proximal direction within the volume of thesyringe body to convey a medicament from the medicament container intothe syringe body, at 14. The moving is performed until a dose indiciafrom a series of dose indicia on the plunger is visible through atransparent window defined by the syringe body. In some embodiments, theplunger includes an engagement portion configured to interface with anengagement portion of the syringe body to limit rotation of the plungerabout a longitudinal axis of the plunger during the moving. In thismanner, the series of dose indicia on the plunger remain radiallyaligned with the transparent window.

In some embodiments, the method optionally includes visually inspectingthe dosage of medicament within the syringe body via a secondtransparent window defined by the syringe body, at 16. In someembodiments, the second transparent window is located distally from thefirst transparent window (e.g., similar to the arrangement shown in FIG.15). In other embodiments, the second transparent window can be anentire transparent portion of a syringe body, as shown and describedabove with respect to the syringe body 210.

The plunger is then moved in a distal direction within the volume of thesyringe body to convey the medicament from the volume via the deliverytip, at 18. In some embodiments, the method can include repeating thedelivery operations multiple times (e.g., on different days and/or doseintervals).

While various embodiments of the invention have been described above, itshould be understood that they have been presented by way of exampleonly, and not limitation. Where methods described above indicate certainevents occurring in certain order, the ordering of certain events may bemodified. Additionally, certain of the events may be performedconcurrently in a parallel process when possible, as well as performedsequentially as described above.

For example, any of the syringe assemblies described herein can includeany suitable engagement mechanism (or mating engagement portions) tolimit rotation of the plunger within the syringe body. For example, anyof the syringe bodies shown and described herein can include anengagement portion similar to the engagement portion 124. Suchengagement portions can include, for example, a protrusion configured tobe disposed within a corresponding groove of the plunger. In otherembodiments, such engagement portions can include a recessed portionconfigured to receive a protrusion of the plunger. In yet otherembodiments, such engagement portions can include a splined surface thatinterfaces with a corresponding splined surface of the plunger to limit,reduce and/or prevent rotation of the plunger within the syringe body.

Any of the transparent windows shown and described herein can be of anysuitable size and/or shape to allow visual access to the indicia.

Any of the plungers shown and described herein can include anelastomeric member, such as the elastomeric member 658 shown anddescribed above. Any such elastomeric member can be constructed from anysuitable material, and can be formulated to be compatible with themedicament housed within the syringe body. Similarly stated, theelastomeric member can be formulated to minimize any reduction in theefficacy of the medicament that may result from contact (either director indirect) between the elastomeric member and the medicament. In someembodiments, at least a portion of the elastomeric member can be coatedto improve the lubricity of the elastomeric member.

Although the syringe assemblies are shown and described herein as beingsuitable for multiple uses (e.g., for a therapeutic regimen over severaldays and/or doses), in other embodiments, any of the syringe assembliesdescribed herein can be configured for a single-use application. In thismanner, the likelihood of using the syringe assembly with the wrongmedicament is reduced. For example, in some embodiments, a syringeassembly can include a locking tab (e.g., on a flange of the syringebody) that engages and retains the plunger in the distal-most positionafter a single dose has been delivered. In other embodiments, thesyringe assembly can include a frangible portion that breaks and/orpermanently deforms such that the plunger cannot be repeatedlyreciprocated within the syringe body.

In some embodiments, a syringe body includes a lock member configured tolimit movement of the distal end portion of the plunger in a proximaldirection within the syringe body after a dose of the medicament hasbeen delivered from the volume of the syringe body.

In some embodiments, a syringe body includes a protrusion configured toengage a portion of the plunger to limit movement of the distal endportion of the plunger in a proximal direction within the syringe bodywhen the distal end portion of the plunger is in a distal-most positionwithin the syringe body.

Any of the devices and/or medicament containers shown and describedherein can be constructed from any suitable material. Such materialsinclude glass, plastic (including thermoplastics such as cyclic olefincopolymers), or any other material used in the manufacture of syringescontaining medications.

Any of the devices and/or medicament containers shown and describedherein can include and/or be used with any suitable medicament ortherapeutic agent. In some embodiments, the medicament contained withinany of the medicament containers and/or syringe assemblies shown hereincan include acetaminophen, ibuprofen, diphenhydramine (Benadryl), coughand cold medicines, vitamins, Prescriptions: azithromycin, albuterol,allopurinol, cefdinir, chloroquine, choleystyramine, doxycycline,enoxaparin, erythromycin, hydroxychloroquine, isoniazid, levofloxacin,magnesium sulfate, methadone, omeprazole, Tamiflu, roxicet, pyridium,Compazinem Phenergan, kayexelate, prednisone, prednisolone, and/ordexamethasone.

The syringe assemblies disclosed herein can contain any suitable amountof any medicament. For example, in some embodiments, a syringe assemblyas shown herein can be sized and/or can define a volume sufficient tocontain any suitable dosage of medicament.

Although various embodiments have been described as having particularfeatures and/or combinations of components, other embodiments arepossible having a combination of any features and/or components from anyof embodiments where appropriate. For example, any of the syringeassemblies described herein can include a detent mechanism of the typesshown and described with respect to the syringe assembly 200.Specifically, any of the syringe bodies shown and described herein caninclude a syringe detent configured to engage one or more plungerdetents to resist movement of the plunger within the syringe body wheneach of a series of indicia is visible through a transparent window. Inthis manner, the user can receive a tactile sensation (e.g., a slightsnap, click or vibration) when each of the indicia are aligned withand/or visible via the transparent window. In this manner, the syringeassembly can allow for a series of discrete intervals of plungermovement within the syringe body.

Any of the kits described herein (e.g., the kit 801 and/or the kit 901)can be used with and/or include any of the syringe assemblies shown anddescribed herein. Similarly stated, each of the kit 801 and the kit 901can include any of the syringe assemblies 100, 200 300, 400, 500, 600,700, 800 and/or 900, and variants thereof.

As another example, any of the syringe bodies described herein caninclude an opaque (or semi-opaque) label similar to that described abovein conjunction with the syringe body 210.

Any of the syringe bodies described herein can include any configurationor arrangement of transparent windows described herein. For example,although the syringe body 110 is shown and described as include only asingle transparent window, in other embodiments, the syringe body 110(and any other syringe body described herein) can include multipletransparent windows as shown in connection with the syringe body 500,the syringe body 600 and/or the syringe body 700.

Any of the syringe bodies shown and described herein can include any ofthe flanges described herein, such as the flange 322.

What is claimed is:
 1. A method of delivering a medicament, comprising:inserting a distal end portion of a plunger into a volume defined by asyringe body through a lateral opening defined in a flange member, thelateral opening between a proximal end portion of the flange member anda distal end portion of the flange member, the distal end portion of theplunger including an elastomeric member, the syringe body having aproximal end portion at a first end and a distal end portion at anopposite second end, the flange member coupled to the proximal endportion of the syringe body; inserting a delivery tip of the syringebody into a medicament container; moving the plunger in a proximaldirection to a proximal position within the syringe body to convey themedicament from the medicament container into the volume, the movingperformed until a dose indicium from a plurality of dose indicia on theplunger is visible through a transparent window defined by the syringebody when the plunger is at the proximal position, the plunger includingan engagement portion configured to interface with an engagement portionof the flange member to limit rotation of the plunger about alongitudinal axis of the plunger during the moving; and moving theplunger in a distal direction within the volume of the syringe bodythrough a distance between the proximal position and a distal positionat the distal end portion of the syringe body to convey the medicamentfrom the volume via the delivery tip, wherein the interface between theengagement portion of the plunger and the engagement portion of theflange member prevents rotation of the plunger about the longitudinalaxis of the plunger when the plunger moves through the distance.
 2. Themethod of claim 1, wherein the moving the plunger in the proximaldirection is performed at a first time to convey a first dose of themedicament, the method further comprising: inserting the delivery tip ofa syringe body into the medicament container at a second time; andmoving the plunger in the proximal direction within the volume of thesyringe body to convey a second dose of the medicament from themedicament container into the volume, the moving the plunger to conveythe second dose performed until the dose indicium from the plurality ofdose indicia on the plunger is visible through the transparent windowdefined by the syringe body.
 3. The method of claim 1, wherein a portionof a side wall surrounding the transparent window is opaque, thetransparent window being sized such that only one dose indicium from theplurality of dose indicia is visible through the transparent window at atime.
 4. The method of claim 3, wherein: the plurality of dose indiciais arranged coaxially along the longitudinal axis of the plunger; theportion of the side wall includes at least one of a framing indicium ora first instruction indicium, the framing indicium at least partiallysurrounding the transparent window; and a proximal end portion of theplunger including a second instruction indicium.
 5. The method of claim1, wherein the transparent window is a first transparent window, themethod further comprising: inspecting visually, before the moving theplunger in the distal direction, the medicament within the volume of thesyringe body via a second transparent window defined by the syringebody, the second transparent window located distally from the firsttransparent window.
 6. The method of claim 1, wherein the moving theplunger in the proximal direction is performed until a syringe detentengages a plunger detent to resist movement of the plunger within thevolume of the syringe body.
 7. The method of claim 1, wherein: thetransparent window is at a first portion of a side wall of the syringebody; the elastomeric member defines a fluid-tight seal with a secondportion of the side wall of the syringe body, the second portion of theside wall of the syringe body and the first portion of the side wall ofthe syringe body having a constant cross-sectional inner diameter; andthe moving the plunger in the distal direction within the volume of thesyringe body includes moving the elastomeric member in the distaldirection within the constant cross-sectional inner diameter.
 8. Themethod of claim 1, wherein: an opaque member is coupled to the syringebody, the opaque member defining an opening such that the opaque memberframes the transparent window, at least one of the opening or thetransparent window being sized such that only one dose indicium from theplurality of dose indicia is visible through the transparent window at atime; and the moving the plunger in the proximal direction to theproximal position includes moving the plunger until the dose indiciumfrom the plurality of dose indicia on the plunger is visible through theopening defined by the opaque member.
 9. The method of claim 8, whereinthe plurality of dose indicia is arranged coaxially along thelongitudinal axis of the plunger and at a constant circumferentialposition along an outer surface of the plunger such that each of theplurality of dose indicia is visible through the transparent window whenthe plunger moves within the volume of the syringe body.
 10. The methodof claim 1, wherein: the transparent window is a first transparentwindow; an opaque member disposed about a side wall of the syringe bodysurrounds the first transparent window; the side wall of the syringebody defines a second transparent window, the second transparent windowlocated distally from the first transparent window such that themedicament within the volume of the syringe body is visible via thesecond transparent window when the dose indicium is visible through thefirst transparent window; and the moving the plunger in the proximaldirection to the proximal position includes moving the plunger in theproximal direction until the dose indicium is visible through the firsttransparent window and the medicament is visible through the secondtransparent window.
 11. The method of claim 1, wherein: the engagementportion of the plunger extends along the longitudinal axis of theplunger; and the moving the plunger in the distal direction includesmaintaining the interface between the engagement portion of the plungerand the engagement portion of the flange member during the moving theplunger in the distal direction through the distance.
 12. The method ofclaim 1, wherein: the engagement portion of the flange member is a slot;the engagement portion of the plunger is matingly received within theslot; and the preventing the rotation of the plunger about thelongitudinal axis of the plunger through the distance results frommaintaining the engagement portion of the plunger within the slot whenthe engagement portion of the plunger moves in the distal directionthrough the distance.
 13. A kit, comprising: a medicament containercontaining a medicament, the medicament container defining an opening;and a syringe assembly including a syringe body and a plunger, aproximal end portion of the syringe body coupled to a flange, a distalend portion of the syringe body including a delivery tip configured tobe disposed within the medicament container to withdraw a dose of themedicament from the medicament container into a volume defined by thesyringe body, a side wall of the syringe body including a transparentwindow, a distal end portion of the plunger configured to move withinthe volume of the syringe body and contact the medicament to convey themedicament, the flange including a distal flange portion and a proximalflange portion, the distal flange portion coupled to the proximal endportion of the syringe body, the proximal flange portion defining alateral opening and an engagement slot, the lateral opening having asize and extending toward the distal flange portion such that the distalend portion of the plunger can be removed from the syringe body via thelateral opening, an engagement portion of the plunger matingly receivedwithin the engagement slot of the flange to prevent rotation of theplunger about a longitudinal axis of the plunger when the distal endportion of plunger moves through a distance between a proximal positionand a distal position at the distal end portion of the syringe body, andan outer surface of the plunger including a plurality of dose indicia,at least one indicium from the plurality of dose indicia being visiblethrough the transparent window.
 14. The kit of claim 13, wherein: thesyringe assembly includes an opaque member surrounding the transparentwindow of the syringe body, the opaque member defining an opening sizedsuch that only one dose indicium from the plurality of dose indicia isvisible through the transparent window at a time; and the plurality ofdose indicia is arranged coaxially along the longitudinal axis of theplunger.
 15. The kit of claim 13, further comprising: a lock memberremovably coupled to the proximal end portion of the syringe body and aproximal end portion of the plunger, the lock member configured to limitmovement of the distal end portion of the plunger within the syringebody, the lock member including an instruction indicium.
 16. The kit ofclaim 13, further comprising: an opaque member coupled to the syringebody, the opaque member defining an opening such that the opaque memberframes the transparent window, the opening being sized such that onlyone indicium from the plurality of dose indicia is visible through thetransparent window at a time.
 17. The kit of claim 13, wherein: theplurality of dose indicia is arranged coaxially along the longitudinalaxis of the plunger and at a constant circumferential position along theouter surface of the plunger such that each of the plurality of doseindicia is visible through the transparent window when the plunger moveswithin the volume of the syringe body.
 18. The kit of claim 13, wherein:the transparent window is at a first portion of the side wall of thesyringe body; and the distal end portion of the plunger including anelastomeric member defining a fluid-tight seal with a second portion ofthe side wall of the syringe body, the second portion of the side wallof the syringe body and the first portion of the side wall of thesyringe body having a constant cross-sectional inner diameter.
 19. Anapparatus, comprising: a syringe body defining a volume configured tocontain a medicament, the syringe body having a proximal end portion, aside wall, and a distal end portion, the distal end portion of thesyringe body including a delivery tip, the side wall including atransparent window portion; a flange member, a distal end portion of theflange member affixed to the proximal end portion of the syringe body, aproximal end portion of the flange member including an engagementportion, the proximal end portion of the flange member defining alateral opening between the engagement portion and the distal endportion of the flange member; and a plunger having a distal end portionincluding an elastomeric member configured to define a fluid-tight sealwith the side wall of the syringe body, the distal end portion of theplunger configured to move within the volume of the syringe body toconvey the medicament, the distal end portion of the plunger configuredto be removed from the volume of the syringe body via the lateralopening, an engagement portion of the plunger configured to interfacewith the engagement portion of the flange member to limit rotation ofthe plunger about a longitudinal axis of the plunger, an outer surfaceof the plunger including a plurality of indicia, at least one indiciumfrom the plurality of indicia being visible through the transparentwindow portion.
 20. The apparatus of claim 19, wherein: the syringeassembly includes an opaque member surrounding the transparent windowportion, the opaque member defining an opening sized such that only onedose indicium from the plurality of dose indicia is visible through thetransparent window portion at a time; the plurality of dose indicia isarranged coaxially along the longitudinal axis of the plunger; and theengagement portion of the plunger includes a splined surface.